Neurocrine BiosciencesLTS:0K6R +1.97%95 Altman Z-Score is 8.96 as of Jul. 08, 2026, which is 2% above its 10-year median of 8.80. GuruFocus rates LTS:0K6R with a GF Score™ of 95/100 and a GF Value™ of $188.99 (Fairly Valued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 83.61% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 8.96 is strong.
Neurocrine Biosciences has a Altman Z-Score of 8.96, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Neurocrine Biosciences's Altman Z-Score or its related term are showing as below:
LTS:0K6R'
s Altman Z-Score Range Over the Past 10 Years
Min: 3.61 Med: 8.8 Max: 52
Current: 8.96
During the past 13 years, Neurocrine Biosciences's highest Altman Z-Score was 52.00. The lowest was 3.61. And the median was 8.80.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Neurocrine Biosciences Altman Z-Score Related Terms
Neurocrine Biosciences Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0K6R vs VTRS, ELAN, UTHR: Altman Z-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Neurocrine Biosciences (LTS:0K6R) has a Altman Z-Score of 8.96 as of Jul. 08, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Neurocrine Biosciences and its competitors. This is near median its historical median of 8.80. Over the past decade, Neurocrine Biosciences' Altman Z-Score has ranged from 3.61 to 52.00. According to the industry distribution chart, Neurocrine Biosciences ranks #156 out of 952 companies in the Drug Manufacturers industry, placing it in the top 16.4%.
Is Neurocrine Biosciences' Altman Z-Score too high?
Neurocrine Biosciences' current Altman Z-Score of 8.96 is near median its 10-year median of 8.80. Over the past 10 years, this metric has ranged from a low of 3.61 to a high of 52.00. The Drug Manufacturers industry median Altman Z-Score is 3.28. Neurocrine Biosciences' value of 8.96 is 173.2% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #156 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Altman Z-Score compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #156 out of 952 companies for Altman Z-Score. This places Neurocrine Biosciences in the top 16% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 3.28. Neurocrine Biosciences' value of 8.96 is 173.2% above this benchmark. Historically, Neurocrine Biosciences' own Altman Z-Score has ranged from 3.61 to 52.00 over the past decade. While the company's 10-year median is 8.80 vs. the industry median of 3.28, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.28, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Altman Z-Score of 8.96 is 173.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Altman Z-Score is 8.96, which is near median its own 10-year median of 8.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Fairly Valued. The stock's GF Value™ is $188.99, compared to a current price of $177.71 — trading 6% below its estimated fair value. The current Altman Z-Score is 8.96, which is near median its 10-year median of 8.80 and 173.2% above the Drug Manufacturers industry median of 3.28. Neurocrine Biosciences' overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current Altman Z-Score is 8.96 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of $177.71 is trading 6% below its estimated GF Value™ of $188.99.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for LTS:0K6R:
Altman Z-Score: 8.96 (near median its 10-year median of 8.80)
GF Value™: $188.99 vs. price of $177.71 (6% below fair value)
Industry Position: 173.2% above the Drug Manufacturers median (#156 of 952)
No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
95GF Score
Get the complete analysis for LTS:0K6R
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0K6R has been successfully added to your 
